TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Infectious Mononucleosis
Research conducted at S.L. Elliott and co-researchers has updated our knowledge about infectious mononucleosis
April 22nd, 2008
"A single blind, randomized, placebo-controlled, single-center phase I clinical trial of a CD8(+) T-cell peptide epitope vaccine against infectious mononucleosis was conducted with 14 HLA B*0801-positive, Epstein-Barr virus (EBV)-seronegative adults. The vaccine comprised the HLA B*0801-restricted peptide epitope FLRGR AYGL and tetanus toxoid formulated in a water-in-oil adjuvant, Montanide ISA 720," researchers in Brisbane, Australia report. "FLRGRAYGL-specific responses were detected in 8/9 peptide-vaccine recipients and 0/4 placebo vaccine recipients by gamma interferon enzyme-linked immunospot assay and/or limiting-dilution analysis. The same T-cell receptor V beta...
Source: TB & Outbreaks Week (2008-04-22)
|
